Tyrosine kinase inhibitors (TKIs) against oncogenic tyrosine kinases (OTK; e.g. BCR-ABL1, EGFRL858R, ERBB2) have created a new era of treatment for OTK leukemia and solid tumors and have substantially improved clinical outcome. Despite their clinical success in chronic myeloid leukemia (CML), resistance to TKIs, such as Imatinib, is a common outcome in most OTK-malignancies. While combination of TKI with conventional chemotherapy results in prolonged survival for most OTK-malignancies, for a large group of patients, no curative treatment option is available. In preliminary work for this proposal we have found that two negative feedback regulators (SPRY2 and DUSP6) are expressed at high levels in OTK-malignancies but not in normal cells or tumor cells lacking an oncogenic tyrosine kinase. The inhibitory linker molecule Sprouty2 (SPRY2) attenuates signal transduction immediately downstream of the oncogenic tyrosine kinase, the Dual Specific Phosphatase DUSP6 interferes with distal signal transduction by dephosphorylation of ERK1/2. Expression levels of these molecules are dependent on the signaling strength of the oncogenic tyrosine kinase and are completely suppressed upon TKI-treatment. Molecules of the Sprouty- and DUSP- families of negative feedback mediators are often inactivated through deletion or promoter hypermethylation in Non- tyrosine kinase tumors but not in OTK-malignancies. Given that SPRY2- and DUSP6-mediated negative feedback signaling was highly active in all OTK-tumor samples studied, we performed experiments that demonstrated that OTK-leukemia cells indeed critically depend on continuous active negative feedback signaling to calibrate otherwise overwhelming tyrosine kinase signaling. In this proposal, we will test the central hypothesis that negative feedback regulators represent a fundamentally novel class of therapeutic targets for the treatment of OTK-leukemias and -solid tumors. The central goal of this proposal is to build a fundamental understanding of how blockade of negative feedback mechanistically leads to cell death in OTK-malignancies (Aims 1-2), and to leverage this mechanistic information towards the development of a new therapy concept based on alternating treatment schedules between TKIs and negative feedback inhibitors (NFIs;
Aim 3).

Public Health Relevance

Targeting negative feedback regulators of oncogenic tyrosine kinases for the treatment of oncogenic tyrosine kinase (OTK) leukemias and solid tumors seems counter intuitive because it represents effectively the opposite of current efforts to improve existing tyrosine kinase inhibitor (TKI)-therapies. However, our preliminary data using genetic mouse models and a small molecule inhibitor of DUSP6 demonstrate an unexpected dependence of OTK-tumor cells on negative feedback regulation. The central goal of this proposal is to build a fundamental understanding of how blockade of negative feedback mechanistically leads to cell death in OTK-malignancies (Aims 1-2), and to leverage this mechanistic information towards the development of a new therapy concept based on alternating treatment schedules between TKIs and pharmacological inhibitors of negative feedback (Aim 3).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA172558-03
Application #
8840549
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Mufson, R Allan
Project Start
2013-07-01
Project End
2018-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
3
Fiscal Year
2015
Total Cost
$328,714
Indirect Cost
$121,214
Name
University of California San Francisco
Department
Pathology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Xiao, Gang; Chan, Lai N; Klemm, Lars et al. (2018) B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell 173:470-484.e18
Martín-Lorenzo, Alberto; Auer, Franziska; Chan, Lai N et al. (2018) Loss of Pax5 Exploits Sca1-BCR-ABLp190 Susceptibility to Confer the Metabolic Shift Essential for pB-ALL. Cancer Res 78:2669-2679
Katerndahl, Casey D S; Heltemes-Harris, Lynn M; Willette, Mark J L et al. (2017) Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol 18:694-704
Schjerven, Hilde; Ayongaba, Etapong F; Aghajanirefah, Ali et al. (2017) Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL. J Exp Med 214:793-814
Chan, Lai N; Müschen, Markus (2017) B-cell identity as a metabolic barrier against malignant transformation. Exp Hematol 53:1-6
Vo, Thanh-Trang T; Lee, J Scott; Nguyen, Duc et al. (2017) mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. Mol Cancer Ther 16:1942-1953
Chan, Lai N; Chen, Zhengshan; Braas, Daniel et al. (2017) Metabolic gatekeeper function of B-lymphoid transcription factors. Nature 542:479-483
Shojaee, Seyedmehdi; Chan, Lai N; Buchner, Maike et al. (2016) PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med 22:379-87
Swaminathan, Srividya; Klemm, Lars; Park, Eugene et al. (2015) Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol 16:766-774
Greaves, Mel; Müschen, Markus (2015) Infection and the Perils of B-cell Activation. Cancer Discov 5:1244-6

Showing the most recent 10 out of 31 publications